Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma

NCT02626962 is registered in ClinicalTrials.gov with Grupo Español Multidisciplinar de Melanoma as lead sponsor.

NCT NCT02626962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2016
Completion date
July 22, 2021
Enrollment
52 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma